Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Antengene Corporation Limited ( (HK:6996) ).
Antengene Corporation Limited announced that the Hong Kong Department of Health has approved two supplemental New Drug Applications for XPOVIO® (selinexor) for additional indications in multiple myeloma and diffuse large B-cell lymphoma. This approval enhances Antengene’s market presence in Hong Kong and potentially broadens its impact on the treatment landscape for these diseases, reinforcing its position as a key player in the biotech industry.
The most recent analyst rating on (HK:6996) stock is a Hold with a HK$4.00 price target. To see the full list of analyst forecasts on Antengene Corporation Limited stock, see the HK:6996 Stock Forecast page.
More about Antengene Corporation Limited
Antengene Corporation Limited is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline includes several in-house discovered programs and a proprietary T cell engager platform, AnTenGager™, designed for broad applicability across autoimmune diseases, solid tumors, and hematological malignancies. Antengene has obtained multiple investigational new drug approvals and submitted new drug applications in various Asia Pacific markets.
Average Trading Volume: 4,412,751
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.83B
For a thorough assessment of 6996 stock, go to TipRanks’ Stock Analysis page.